Slide 1: Defining life's signals
INVESTOR PRESENTATION | FY26 RESULTS | SEPTEMBER 2026 For personal use only Defining life’s signals FY26 was a record year: sales up 18.5%, EBITDA up 74%, back in profit and generating cash. In FY27 we aim to grow sales by double digits again and lift margins further. $60.3M $5.4M $6.6M Cash from op
Slide 2: Business Snapshot
BUSINESS SNAPSHOT A global medical technology company with six revenue segments - now entering a new phase of growth SIX REVENUE SEGMENTS, ONE PLATFORM Sleep - clinical diagnostics Sleep-lab systems (Grael, PSG) used by hospitals and clinics For personal use only Compumedics makes the equipment and
Slide 3: Executive Summary
EXECUTIVE SUMMARY FY26 in short: record sales, profit up sharply and much stronger cash For personal use only SALES ORDERS SALES REVENUE - A RECORD EBITDA $62.7M $60.3M $5.4M Orders slightly ahead of sales (1.04x) Up +18.5% on FY25 Up +74.3% on FY25 $28.3M of orders still to deliver in FY27 Up +21%
Slide 4: FY27 at a Glance
FY27 AT A GLANCE FY27: double-digit sales growth, wider margins, and three clear steps from a platform that already works For personal use only Sales revenue ($M) EBITDA ($M) and EBITDA margin Objective: another year of double-digit growth Objective: EBITDA to grow faster than sales - margin expands
Slide 5: The FY26 result
01 For personal use only SECTION 01 The FY26 result Record revenue, EBITDA up 74%, a return to profit and materially stronger cash generation - the year the operating model demonstrated its leverage. Compumedics Limited (ASX: CMP) | FY26 investor presentation | September 2026 5
Slide 6: FY26 Financial Results
FY26 FINANCIAL RESULTS Earnings momentum through revenue growth, recurring revenue expansion and cost discipline Sales Orders ($M) Sales Revenue ($M) USA Revenue ($M) For personal use only 1.04x book-to-bill; $28.3M open orders into FY27 Record revenue FY26, up +18.5% YoY -6% YoY during the U.S. com
Slide 7: FY26 Financial Performance
FY26 FINANCIAL PERFORMANCE A step-change in earnings quality, profitability and cash generation Operating leverage demonstrated Revenue up 18.5% and EBITDA up 74.3%, with margin lifting to 9% - evidence of For personal use only 30 June FYE | $M FY23A FY24A FY25A FY26A the scalability of the operatin
Slide 8: The FY26 Bridge
THE FY26 BRIDGE $14.2 million of growth from MEG, SaaS and consumables absorbed a temporary $4.9 million decline in capital equipment Growth Decline Total revenue For personal use only +4.2 +0.3 (2.1) (2.6) +9.7 (0.2) 60.3 50.8 FY25 Consumables Sleep Neuro DWL FY26 MEG SaaS revenue & care capital ca
Slide 9: The FY26 EBITDA Bridge
THE FY26 EBITDA BRIDGE EBITDA up 74%: gross profit growth, other income and delivered cost savings funded a step-up in expensed R&D Growth Decline Total EBITDA $M | constructed from the audited FY26 income statement; components sum to reported FY25 and FY26 EBITDA; FX and D&A shown net. For personal
Slide 10: Business Model & Revenue Diversification
BUSINESS MODEL & REVENUE DIVERSIFICATION A diversified revenue base across multiple geographies and segments GEOGRAPHY - FY26 REVENUE SEGMENT - FY26 REVENUE For personal use only Asia-Pacific 61% Sleep - clinical diagnostics 27% Somfit & Nexus 360 SaaS 17% Americas 27% Neuro monitoring & research 19
Slide 11: The platform & growth engines
02 For personal use only SECTION 02 The platform & growth engines What Compumedics is, how 39 years of engineering built six revenue segments, the markets they address - and where each is heading in FY27. Compumedics Limited (ASX: CMP) | FY26 investor presentation | September 2026 11
Slide 12: The Arc, 1986 - 2026
THE ARC, 1986 - 2026 Three eras of value creation: an engineering contract, an acquisition platform, and an emerging subscription business For personal use only 01 02 03 1986 - 2000 2001 - 2020 2021 - 2026 The founding insight Building the platform From boxes to subscriptions Solve one hospital’s pr
Slide 13: Product Evolution 1995 - 2026
PRODUCT EVOLUTION | 1995 - 2026 56 times lighter in 30 years - the precondition for selling studies instead of boxes Regulatory clearance opened the market; miniaturisation is what made the study itself sellable - and a study is what you can sell by subscription. For personal use only 1995 2000 2007
Slide 14: The Market Opportunity
THE MARKET OPPORTUNITY A large, under-diagnosed market shifting toward home-based, wearable and cloud- delivered care For personal use only THE ADDRESSABLE MARKETS - $B THE STRUCTURAL SHIFT U.S. HOME SLEEP TESTING Home sleep testing +9.7% CAGR From the laboratory to the home $2.0-2.1B | 2025 Patient
Slide 15: Revenue Model
REVENUE MODEL Building a more recurring, visible and valuable revenue model Compumedics has historically generated a significant proportion of revenue from sophisticated capital equipment. That installed base remains a competitive advantage - but the model is evolving: approximately 1,600 systems ar
Slide 16: Sleep - Clinical Diagnostics
SLEEP - CLINICAL DIAGNOSTICS An established global sleep diagnostics business - and the foundation of the recurring model FY26 revenue of $16.1M, down 11% on a strong FY25. Sales orders of $18.2M exceeded revenue - management attributes the shortfall to the timing of shipment and invoicing rather th
Slide 17: Sleep - Somfit & Nexus SaaS
SLEEP - SOMFIT & NEXUS 360 SAAS Somfit is evolving from a diagnostic device into a scalable digital sleep platform Somfit & Nexus 360 SaaS revenue ($M) WHY THE MODEL IS STRATEGICALLY ATTRACTIVE The U.S. opportunity for Somfit For personal use only Recurring economics Revenue is generated repeatedly
Slide 18: Neuro Monitoring & Research
NEURO MONITORING & RESEARCH A globally established neurotechnology platform supporting growth, cross-sell and innovation Products spanning EEG, Okti, Neuroscan and CURRY are used across clinical and research settings, supporting applications from epilepsy monitoring to advanced neuroscience research
Slide 19: MEG
MEG OrionMEG is transitioning into a high-value global commercial platform The strategic significance of MEG has changed materially over the past year. Twelve months ago the proposition centred on pending installations and future potential. FY26 provided clear commercial evidence. For personal use o
Slide 20: DWL Bloodflow & TCD
DWL BLOODFLOW & TCD An established global business with a clear operational reset and differentiated technology upside The near-term priority is operational performance. Management is focused on improving the efficiency, competitiveness and scalability of the underlying DWL business while continuing
Slide 21: Consumables & Customer Care
CONSUMABLES & CUSTOMER CARE A growing installed base drives durable, recurring revenue FY26 revenue of $8.1M, up 4%. Consumables, service and support generate recurring revenue across Compumedics’ global installed base of more than 25,000 systems. For personal use only Embedded recurring revenue Att
Slide 22: Why now & the path ahead
03 For personal use only SECTION 03 Why now & the path ahead The evidence behind the thesis, how the business creates value, and the FY27 objective: further double-digit revenue growth, with EBITDA growing at a faster rate than revenue. Compumedics Limited (ASX: CMP) | FY26 investor presentation | S
Slide 23: Why Compumedics, Why Now
WHY COMPUMEDICS, WHY NOW From promise to proof: FY26 put evidence behind every pillar of the investment thesis TWELVE MONTHS AGO FY26 - DELIVERED THE UPSIDE AHEAD For personal use only Growth Revenue up 2% in FY25; the thesis rested on Record revenue $60.3M, up 18.5% - 1.04x book-to-bill Further dou
Slide 24: Value Creation
VALUE CREATION How we create value: grow, improve the mix, leverage the base, convert to cash For personal use only 01 Grow 02 Improve the mix 03 Leverage the base 04 Convert to cash +18.5% 30% 4.0x $6.6M Record FY26 revenue of $60.3M; further Of revenue now recurring (FY24: 25%), led by EBITDA grew
Slide 25: FY27 & The Destination
FY27 & THE DESTINATION Build on the progress: another year of profitable growth on the way to a larger, more recurring, more profitable company For personal use only “Compumedics remains focused on delivering further double-digit revenue growth in FY27, with EBITDA growth at a faster rate than reven
Slide 26: Disclaimer
DISCLAIMER This presentation has been prepared by Compumedics Limited (ACN 006 854 897) (CMP). It contains summary information about CMP and its activities current as at September 2026, including audited financial information for the year ended 30 June 2026. All figures are in Australian dollars (AU
Slide 27: Thank you
For personal use only INVESTOR PRESENTATION | FY26 RESULTS | SEPTEMBER 2026 Thank you Compumedics Limited (ASX: CMP) | Melbourne, Australia | compumedics.com.au Dr David Burton David Lawson Executive Chairman & Chief Executive Officer Director & Chief Financial Officer P: +61 3 8420 7300 P: +61 3 84